AUTL - Company ID 0001730463
The table below shows Autolus Therapeutics plc's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$65.32M | -$75.56M | -$40.51M | -$42.42M | -$37.34M | -$24.03M |
| Capital expenditure | $2.69M | $8.24M | $533.00K | $3.62M | $1.90M | $2.64M |
| Investing cash flow | $96.15M | -$59.55M | -$533.00K | -$3.62M | -$1.90M | -$2.64M |
| Dividends paid | - | - | - |
Autolus Therapeutics plc reported operating cash flow of -$283.57M for fiscal year 2025. That is down 37.5% from -$206.27M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$9.85M (FY 2016) to -$283.57M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$2.06M | $0.00 | $561.44M | -$691.00K | $123.32M | $74.31M |